Skip to main content

DESARROLLO DE VACUNAS DIVA UNIVERSALES FRENTE AL VIRUS DE LA LENGUA AZUL BASADAS EN RESPUESTA INMUNE CELULAR INDUCIDA POR LAS PROTEINAS NO ESTRUCTURALES DEL VIRUS CONSERVADAS

AGL2017-82570-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA - CSIC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

AGL2017-82570-RReverse genetics approaches for the development of new vaccines against influenza A virus infections

  • Martínez-Sobrido, Luis
  • DeDiego, Marta L.
  • Nogales, Aitor
Influenza A viruses (IAVs) represent a serious concern globally because they are capable of rapid spread and cause severe disease in humans and other animals. The development and implementation of plasmid-based reverse genetics approaches have allowed the manipulation and recovery of recombinant IAVs from complementary DNA copies of the viral genome. Furthermore, IAV reverse genetics have provided researchers an efficient and powerful platform to introduce specific changes in the viral genome with the final goal of studying IAV biology, designing more effective vaccine strategies, and to reduce the rates of incidence and mortality associated with viral infections. In this review, we briefly discuss IAV reverse genetics and their applications to prevent IAV infections., Influenza research in LM-S laboratory has been partially funded by the New York Influenza Center of Excellence (NYICE, NIH 272201400005C), a member of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract No. HHSN272201400005C (NYICE), the NIH/NIAID 1R01AI145332, and the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP) grant W81XWH-18-1-0460. Research in M.L.D laboratory was supported with funds from Comunidad de Madrid, Spain, reference 2017-T1/BMD-5155 and the Spanish Ministry of Science, Innovation and Universities (RTI-2018-094213-A-I00). Research in A.N laboratory was partially funded with the ‘Ramon y Cajal’ Fellowship RYC-2017 from Spanish Ministry of Economy, Industry and Competitiveness and the Spanish Ministry of Science, Innovation and Universities (AGL2017-82570-R).